Literature DB >> 11585416

Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement.

A Mariani1, M J Webb, G L Keeney, G Calori, K C Podratz.   

Abstract

OBJECTIVE: The goal of this work was to assess retrospectively the role of wide/radical hysterectomy (RH) and pelvic lymph node dissection (LND) in endometrial cancer with cervical involvement. METHODS; From 1984 to 1993, 82 patients with endometrial cancer and cervical involvement were surgically managed at our institution. Of 57 patients with stage II (59%) or III (41%) disease receiving no preoperative therapy, 22 (39%) had simple hysterectomy (SH) and 35 (61%) had RH. Forty-four patients (77%) had pelvic LND, and 38 (67%) had adjuvant radiotherapy (RT). Median follow-up was 70 months.
RESULTS: The 5-year disease-related survival (DRS) and recurrence-free survival (RFS) were 73 and 63%, respectively. Five-year DRS and RFS were 68 and 50%, respectively, in the SH group compared with 76% (P = 0.1) and 71% (P = 0.04) in the RH group. Distant recurrences occurred in 45% of patients with SH and in 23% with RH (P = 0.08). Local recurrence rates did not differ significantly. Considering only stage II tumors, we did not observe any recurrence among patients with negative nodes who had RH, irrespective of the administration of adjuvant RT. By contrast, adjuvant RT improved local control (even if not significantly) in stage II patients who had SH. Five-year DRS of stage III patients was 47%, but it was improved by adjuvant RT in the subgroup of patients who had RH. Independent variables associated with prognosis were stage III disease, deep myometrial invasion, RH, and adjuvant RT.
CONCLUSION: RH and adjuvant RT appear to improve prognosis in endometrial cancer with cervical involvement. In particular, radical surgery alone is therapeutic in stage II patients with negative nodes, irrespective of the administration of RT. By contrast, RT can possibly improve local control in stage II patients who previously had SH. Overall, stage III patients have a poor prognosis that can be improved by a combination of radical surgery and adjuvant RT; however, associated therapy directed to extrapelvic sites is probably needed in patients with extrauterine disease. Copyright 2001 Academic Press.

Entities:  

Mesh:

Year:  2001        PMID: 11585416     DOI: 10.1006/gyno.2001.6346

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  18F-FDG PET in the management of endometrial cancer.

Authors:  Angel Chao; Ting-Chang Chang; Koon-Kwan Ng; Swei Hsueh; Huei-Jean Huang; Hung-Hsueh Chou; Chien-Sheng Tsai; Tzu-Chen Yen; Tzu-I Wu; Chyong-Huey Lai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-16       Impact factor: 9.236

Review 2.  Endometrial cancer: the management of high-risk disease.

Authors:  Gunnar Kristensen; Claes Tropé
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

3.  Controversies in the management of endometrial cancer.

Authors:  V Masciullo; G Amadio; D Lo Russo; I Raimondo; A Giordano; G Scambia
Journal:  Obstet Gynecol Int       Date:  2010-06-16

4.  Controversies in the management of endometrial carcinoma.

Authors:  Ying Zhang; Jian Wang
Journal:  Obstet Gynecol Int       Date:  2010-06-22

5.  Surgical management and postoperative treatment of endometrial carcinoma.

Authors:  Jason A Lachance; Christopher J Darus; Laurel W Rice
Journal:  Rev Obstet Gynecol       Date:  2008

6.  Radical hysterectomy with pelvic lymphadenectomy: indications, technique, and complications.

Authors:  Rachel A Ware; John R van Nagell
Journal:  Obstet Gynecol Int       Date:  2010-09-01

7.  Cancer of the corpus uteri: 2021 update.

Authors:  Martin Koskas; Frédéric Amant; Mansoor Raza Mirza; Carien L Creutzberg
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

8.  Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?

Authors:  M Takano; H Ochi; Y Takei; M Miyamoto; Y Hasumi; Y Kaneta; K Nakamura; A Kurosaki; T Satoh; H Fujiwara; S Nagao; K Furuya; H Yokota; K Ito; T Minegishi; H Yoshikawa; K Fujiwara; M Suzuki
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

9.  Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.

Authors:  Shin Wha Lee; Taek Sang Lee; Dae Gy Hong; Jae Hong No; Dong Choon Park; Jae Man Bae; Seok Ju Seong; So Jin Shin; Woong Ju; Keun Ho Lee; Yoo Kyung Lee; Hanbyoul Cho; Chulmin Lee; Jiheum Paek; Hyun Jung Kim; Jeong Won Lee; Jae Weon Kim; Duk Soo Bae
Journal:  J Gynecol Oncol       Date:  2016-10-27       Impact factor: 4.401

10.  Does the extension of the type of hysterectomy contribute to the local control of endometrial cancer?

Authors:  Tetsuya Hasegawa; Megumi Furugori; Kazumi Kubota; Mikiko Asai-Sato; Aiko Yashiro-Kawano; Hisamori Kato; Yuka Oi; Hiroyuki Shigeta; Keiko Segawa; Masakazu Kitagawa; Yuko Mine; Haruya Saji; Reiko Numazaki; Yasuyo Maruyama; Emi Ohnuma; Hanako Taniguchi; Ken Sugiura; Etsuko Miyagi; Tatsuya Matsunaga
Journal:  Int J Clin Oncol       Date:  2019-05-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.